Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pathol.2020.01.680 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC).
J Clin Transl Endocrinol
December 2024
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as or fusions and pathogenic mutations of the and genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%.
View Article and Find Full Text PDFUpdated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection - Update 1.
Neuro Oncol
October 2024
Division of Oncology, Department of Medicine 1, Medical University, Vienna, Austria ORCID iD 0000-0003-3541-2315.
The standard of care for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a major part of the standard treatment, however, the predictive significance of most of the targets for treatment in systemic cancer are less well established in central nervous system (CNS) tumors . In 2023 the EANO Guideline Committee presented evidence based recommendations for rational testing of molecular targets for targeted treatments.
View Article and Find Full Text PDFMolecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?
Curr Oncol Rep
November 2024
Department of Neurology and Neurosurgery, Thomas Jefferson University, 901 Walnut St, Room 310G, Philadelphia, PA, 19107, USA.
Article Synopsis
- Scientists and doctors need to look at specific traits in glioma tumors to figure out the best diagnosis and treatment.
- New rules from the WHO and FDA show that testing these traits can really help in treating glioma patients.
- Certain gene changes can help doctors use special drugs and find other treatments that could help people with gliomas.
Cytologic testing for mismatch repair deficiency/microsatellite instability and NTRK gene fusion is not routinely indicated in primary pancreaticobiliary carcinoma cell block material.
J Am Soc Cytopathol
November 2024
Department of Pathology and Laboratory Medicine, University of California Irvine Health School of Medicine, Sacramento, California. Electronic address:
Introduction: Pancreaticobiliary carcinomas rarely harbor targetable genetic alterations, including microsatellite instability (MSI) or neurotrophic tyrosine receptor kinase (NTRK) gene fusions. As these malignancies are typically present at an advanced stage and have suboptimal response to chemotherapy, the discovery of an actionable genomic alteration provides an additional avenue of treatment for chemotherapy-refractory cases.
Materials And Methods: In this study, we evaluate 319 cases of pancreaticobiliary carcinoma diagnosed on fine-needle aspiration biopsy or biliary brushing for DNA mismatch repair (MMR) protein deficiency and pan-TRK overexpression by immunohistochemistry (IHC) and compare these results to MSI and NTRK gene fusion molecular testing.
A pilocytic astrocytoma with novel ATG16L1::NTRK2 fusion responsive to larotrectinib: a case report with genomic and functional analysis.
Oncologist
September 2024
Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
The outcome of pilocytic astrocytoma (PA) depends heavily on the success of surgery. In cases where surgery alone is not curative, genetic analysis can be used to identify treatment targets for precision medicine. Here, we report a pediatric PA case that underwent incomplete surgical resection due to the tumor location.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!